IRONWOOD PHARMACEUTICALS, INC. Amortization of Intangible Assets
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Amortization of Intangible Assets of $8.11 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2021-02-17
- IRONWOOD PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2018-09-30 was $1.16M, a 38.90% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2018-06-30 was $3.48M, a 725.65% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2018-03-31 was $3.48M, a 727.62% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2018 was $8.11M, a 30.53% increase from fiscal 2017.
- IRONWOOD PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2017 was $6.21M, a 533.44% increase from fiscal 2016.
- IRONWOOD PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2016 was $981.00K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $1.16M derived: sum of 2 quarters · filed 2021-02-17 | $4.63M derived: sum of 3 quarters · filed 2021-02-17 | $8.11M 10-K · filed 2021-02-17 | |
| 2018-09-30 | $1.16M 10-Q · filed 2019-10-31 | $4.63M derived: sum of 2 quarters · filed 2019-10-31 | $8.11M 10-Q · filed 2019-10-31 | $11.59M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-06-30 | $3.48M 10-Q · filed 2019-07-30 | $6.95M 10-Q · filed 2019-07-30 | $10.43M derived: sum of 3 quarters · filed 2020-02-13 | $12.32M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-03-31 | $3.48M 10-Q · filed 2019-05-02 | $6.95M derived: sum of 2 quarters · filed 2020-02-13 | $8.85M derived: sum of 3 quarters · filed 2020-02-13 | $9.27M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2017-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $5.37M derived: sum of 2 quarters · filed 2020-02-13 | $5.79M derived: sum of 3 quarters · filed 2020-02-13 | $6.21M 10-K · filed 2020-02-13 | |
| 2017-09-30 | $1.90M 10-Q · filed 2018-11-06 | $2.32M derived: sum of 2 quarters · filed 2018-11-06 | $2.74M 10-Q · filed 2018-11-06 | $6.04M derived: sum of 4 quarters · filed 2018-11-06 | |
| 2017-06-30 | $421.00K 10-Q · filed 2018-08-06 | $841.00K 10-Q · filed 2018-08-06 | $4.14M derived: sum of 3 quarters · filed 2018-08-06 | $7.34M derived: sum of 4 quarters · filed 2018-08-06 | |
| 2017-03-31 | $420.00K 10-Q · filed 2018-05-04 | $3.72M derived: sum of 2 quarters · filed 2018-05-04 | $6.92M derived: sum of 3 quarters · filed 2018-05-04 | $7.99M derived: sum of 4 quarters · filed 2018-05-04 | |
| 2016-12-31 | $3.30M 10-K · filed 2018-02-22 | $6.50M derived: sum of 2 quarters · filed 2018-02-22 | $7.57M derived: sum of 3 quarters · filed 2018-02-22 | $981.00K 10-K · filed 2019-02-25 | |
| 2016-09-30 | $3.20M 10-K · filed 2018-02-22 | $3.21M 10-Q · filed 2016-11-07 | $4.26M derived: sum of 2 quarters · filed 2018-02-22 | $4.28M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $1.06M 10-Q · filed 2017-08-03 | $1.06M 10-Q · filed 2017-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |